Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland

Amphetamine Dependence Clinical Trial

Official title:

Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01100853
• Other study ID #: 811095
• Secondary ID: P50DA0127562009-
• Status: Completed
• Phase: Phase 3
• First received: April 7, 2010
• Last updated: March 2, 2018
• Start date: May 2010
• Est. completion date: February 2013

Study information

• Verified date: March 2018
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Until positive results were found with oral naltrexone, no medication has been effective against amphetamine dependence. The primary aim of this pilot study is to replicate the findings of the Swedish team that showed oral Naltrexone prevented relapse to amphetamine addiction and to extend their results by randomizing treatment-seeking amphetamine addicted patients to a 6 month course of VIVITROL (naltrexone for extended-release injectable suspension) or VIVITROL placebo. Patients in each group will receive drug counseling. VIVITROL is administered monthly and may be a better test of efficacy than tablets that must be taken daily.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 or above;

2. Diagnosis of amphetamine dependence as defined by DSM-IV-TR with 10 or more days of amphetamine use in the past month, and patient and clinician identify amphetamine dependence as the main problem;

3. Abstinent from substances (alcohol, amphetamines, cannabinoid, cocaine, hallucinogens, opioids, benzodiazepines [unless used to treat alcohol withdrawal] for at least 7 days prior to receiving study drug or placebo;

4. Provision of telephone numbers/contacts of three or more people that are likely to know where can be located if unable to be contacted directly;

5. Successfully complete 7-10 day assessment and study baseline measures at Vogur

Exclusion Criteria:

1. Any liver test >5 times the top limit of normal; Physiologically dependent on opioids or other substances (nicotine excepted) at time of admission to Vogur;

2. Suspected or known concomitant use of opioid analgesics, positive opioid urine drug test or positive naloxone challenge:

3. Schizophrenia, Bipolar I or other non-substance related psychotic disorder; Severely depressed, suicidal or homicidal: Dementia: Inability to understand the informed consent;

4. Planning to move from the Reykjavík area or enter jail within the next 12 months;

5. Likely to receive opioid analgesics in next 6 months associated with possible or scheduled surgery or procedure;

6. Known hypersensitivity to naltrexone, polyactide-co-glycolide (PLG); carboxymethylcellulose, or any other component of the diluent;

7. Female subjects who are pregnant or lactating, or of child bearing potential who are not using acceptable methods of birth control;

8. A body habitus that precludes use of the customized needle for intramuscular injection, based on clinical judgment;

9. Use of an investigational agent in the past 30 days

Related Conditions & MeSH terms

• Amphetamine Dependence
• Amphetamine-Related Disorders

Intervention

Drug:
• VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)

Locations

Country	Name	City	State
Iceland	SAA National Center of Addiction Medicine, Vogur Hospital	Storhofda 45	Reykjavík

Sponsors (3)

Lead Sponsor	Collaborator
University of Pennsylvania	National Institute on Drug Abuse (NIDA), Society of Alcoholism and other Addictions

Country where clinical trial is conducted

Iceland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number Negative Urines (Proportion Negative Urines)		24 Weeks
Primary	Number Negative Urines (Proportion Negative Urines) Amphetamine		24 weeks
Secondary	Amphetamine Craving Scale	The Amphetamine Craving Scale is a visual analogue scale, which is scored by indicating the level of craving on a 100 mm line, where 0 is no craving at all and 100 is the highest level of craving experienced. Scores are derived from measuring their placement on the line, yielding scores from 0 to 100.	24 weeks
Secondary	Beck Depression Inventory	The Beck Depression Inventory is a self-administered questionnaire that assess the severity of depressive symtpoms. It consists of 21 items about how the subject has been feeling in the last week, and each item has a set of at least four possible answer choices, ranging in intensity, yielding scores from 0-3, with a total possible score of 63. Higher scores indicate more severe depressive symptoms.	24 weeks
Secondary	Risk Assessment Battery	The Risk Assessment Battery is a 41 item self-report questionnaire that assess risk behaviors related to HIV infection over the past 6 months. The measure yields a Drug risk score ranging from 0-22 and a Sex risk score ranging from 0-18, with higher scores indicating more risk; these scores are added to yield a Total RAB score ranging from 0-40. This total scores is then divided by 40 to yield a RAB Scale Score from 0-1.	24 weeks
Secondary	Prior Admissions to Vogur Hospital	Number of prior admissions due to substance dependence. The term "prior admissions" refers to admissions before enrollment, thus Baseline is the appropriate Time Frame.	Baseline